BNTX Stock Overview
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
BioNTech SE Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$92.97 |
52 Week High | US$131.52 |
52 Week Low | US$85.21 |
Beta | 0.23 |
1 Month Change | -0.59% |
3 Month Change | -12.06% |
1 Year Change | -24.40% |
3 Year Change | -14.85% |
5 Year Change | n/a |
Change since IPO | 552.88% |
Recent News & Updates
We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24Recent updates
We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%
Nov 19BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09CDC advisory panel recommends COVID vaccines for children be included in federal program
Oct 19Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?
Oct 18Hong Kong approves BioNTech COVID vaccine for infants
Oct 12EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids
Oct 03BioNTech: A Tale Of 2 Companies
Sep 20European drug regulator panel backs approval of Pfizer/BioNTech's Omicron-adapted shot
Sep 12CDC advisors to vote on COVID Omicron vaccines on Sept. 1
Aug 30Shareholder Returns
BNTX | US Biotechs | US Market | |
---|---|---|---|
7D | 3.3% | 0.9% | 0.4% |
1Y | -24.4% | 10.3% | 28.8% |
Return vs Industry: BNTX underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: BNTX underperformed the US Market which returned 28.8% over the past year.
Price Volatility
BNTX volatility | |
---|---|
BNTX Average Weekly Movement | 4.5% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BNTX has not had significant price volatility in the past 3 months.
Volatility Over Time: BNTX's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 6,133 | Ugur Sahin | https://www.biontech.de |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors.
BioNTech SE Fundamentals Summary
BNTX fundamental statistics | |
---|---|
Market cap | US$22.10b |
Earnings (TTM) | US$1.01b |
Revenue (TTM) | US$4.13b |
21.9x
P/E Ratio5.3x
P/S RatioIs BNTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BNTX income statement (TTM) | |
---|---|
Revenue | €3.82b |
Cost of Revenue | €599.80m |
Gross Profit | €3.22b |
Other Expenses | €2.29b |
Earnings | €930.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
Earnings per share (EPS) | 3.91 |
Gross Margin | 84.29% |
Net Profit Margin | 24.36% |
Debt/Equity Ratio | 0.01% |
How did BNTX perform over the long term?
See historical performance and comparison